Floatz logo

Napazimone

MELAS Syndrome

Abliva ABSmall moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the MELAS Syndrome cohort.

Asset / SponsorPhaseRating
Sonlicromanol
Khondrion BV
Phase 3BB
Fluzone
Stanford University
Phase 4BB
Idebenone
Michio Hirano
Phase 2B
ARG
The Hospital for Sick Children
Phase 2B
Zagociguat
Tisento Therapeutics
Phase 2CCC

View all 10 →

Same molecule, other indications

Napazimone is also rated in:

mitochondrial diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
Mitochondrial Respiratory Chain DeficienciesDormant
CCC
Indicative ·
52 / 100
View asset →
inborn mitochondrial myopathyDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →